Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy

Journal of Diabetes

Volumn 7, Issue 2, 2015, Pages 182-191

  Cheng, Qingfeng ^a   Yang, Shumin ^a   Zhao, Changhong ^a   Wang, Zhihong ^a   Feng, Zhengping ^a   Li, Rong ^a   Ye, Peng ^a   Zhang, Suhua ^a   Deng, Huacong ^a   Zhou, Bo ^a   Long, Jian ^a   Gong, Lilin ^a   Qing, Hua ^a   Luo, Cheng ^a   Li, Qifu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Glargine; Intensive insulin therapy; Metformin; Type 2 diabetes mellitus

Indexed keywords

GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIABETIC PATIENT; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT CHANGE; ANALYSIS; CHINA; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROGNOSIS; RISK FACTOR;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; CHINA; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RISK FACTORS;

EID: 84924146782     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12167     Document Type: Article

References (24)

1. Wang CC, Reusch JE. Diabetes and cardiovascular disease: Changing the focus from glycemic control to improving long-term survival. Am J Cardiol. 2012; 110: 58B-68B.
2. Standards of medical care in diabetes: 2013. Diabetes Care. 2013; 36 (Suppl. 1): S11-66.
3. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379.
4. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008; 31: 1927-1932.
5. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-3086.
6. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005; 28: 950-955.
7. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006; 23: 736-742.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419.
9. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22: 1462-1470.
10. Herzberg-Schafer SA, Staiger H, Heni M etal. Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired beta-cell function. PLoS ONE. 2010; 5: e14194.
11. Bi Y, Zhu D, Jing Y etal. Decreased beta cell function and insulin sensitivity contributed to increasing fasting glucose in Chinese. Acta Diabetol. 2012; 49 (Suppl. 1): 51-58.
12. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C (ed.). Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Harwood Academic Publishers, Chur, Switzerland, 1994, 111-132.
13. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: The ADDQoL. Qual Life Res. 1999; 8: 79-91.
14. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981; 68: 1456-1467.
15. Denti P, Toffolo GM, Cobelli C. The disposition index: From individual to population approach. Am J Physiol Endocrinol Metab. 2012; 303: E576-586.
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-865.
17. Roden M, Laakso M, Johns D etal. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabet Med. 2005; 22: 1101-1106.
18. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. Beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012; 35: 1406-1412.
19. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009; 32: 1335-1343.
20. Haak T. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia. Adv Ther. 2012; 29: 1005-1015.
21. Chen A, Huang Z, Wan X etal. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care. 2012; 35: 474-481.
22. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004; 27: 1028-1032.
23. Weng J, Li Y, Xu W etal. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet. 2008; 371: 1753-1760.
24. Chon S, Oh S, Kim SW, Kim JW, Kim YS, Woo JT. The effect of early insulin therapy on pancreatic beta-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients. Korean J Intern Med. 2010; 25: 273-281.